Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD
Sponsor: Premier Research
Listed as NCT03062540, this PHASE3 trial focuses on PTSD and remains terminated or withdrawn. Sponsored by Premier Research, it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 11 earlier versions
-
Apr 2022 — Jun 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Oct 2019 — Nov 2020 [monthly]
Terminated PHASE3
-
Aug 2018 — Oct 2019 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — May 2017 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Premier Research
- Tonix Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .